

Publications – Prof. Paolo Ferrari, MBBS MD FRACP FASN FERA

ORCID: [0000-0002-9619-3104](https://orcid.org/0000-0002-9619-3104)

Researchgate: [Researchgate.net](https://www.researchgate.net/profile/Paolo-Ferrari)

Google scholar: [Google scholar](https://scholar.google.com/citations?user=0000-0002-9619-3104)



Citation indices	All	Since 2013
Citations	7228	2251
h-index	48	25
i10-index	119	68

Original articles

1. Chen, J. H. C., Hughes, P., Woodroffe, C., & **Ferrari, P.** (2018). Pre- and postdonation kidney function in donors of a kidney paired donation with unique criteria for donor glomerular filtration rate - a longitudinal cohort analysis. *Transpl Int*. doi:[10.1111/tri.13366](https://doi.org/10.1111/tri.13366)
2. Allen, R. D. M., Pleass, H. C. C., Woodroffe, C., Clayton, P. A., & **Ferrari, P.** (2018). Challenges of kidney paired donation transplants involving multiple donor and recipient surgeons across Australia. *ANZ Journal of Surgery*, 88(3), 167-171. doi:[10.1111/ans.13517](https://doi.org/10.1111/ans.13517)
3. Gummer, J., Trengove, R., Pascoe, E. M., Badve, S. V., Cass, A., Clarke, P., . . . **Ferrari, P.** (2017). Association between serum hepcidin-25 and primary resistance to erythropoiesis-stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial. *Nephrology*, 22(7), 548-554. doi:[10.1111/nep.12815](https://doi.org/10.1111/nep.12815)
4. Sypek, M. P., Alexander, S. I., Cantwell, L., Ierino, F. L., **Ferrari, P.**, Walker, A. M., & Kausman, J. Y. (2017). Optimizing Outcomes in Pediatric Renal Transplantation Through the Australian Paired Kidney Exchange Program. *American Journal of Transplantation*, 17(2), 534-541. doi:[10.1111/ajt.14041](https://doi.org/10.1111/ajt.14041)
5. Holman, R., Olynyk, J. K., Kulkarni, H., & **Ferrari, P.** (2017). Characterization of hepatic and cardiac iron deposition during standard treatment of anaemia in haemodialysis. *Nephrology*, 22(2), 114-117. doi:[10.1111/nep.12735](https://doi.org/10.1111/nep.12735)
6. **Ferrari, P.**, Cantwell, L., Ta, J., Woodroffe, C., D'Orsogna, L., & Holdsworth, R. (2017). Providing better-matched donors for HLA mismatched compatible pairs through kidney paired donation. *Transplantation*, 101(3), 642-648. doi:[10.1097/TP.0000000000001196](https://doi.org/10.1097/TP.0000000000001196)
7. Zhang, L., Coombes, J., Pascoe, E. M., Badve, S. V., Dalziel, K., Cass, A., . . . Johnson, D. W. (2016). The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial. *Redox Report*, 21(1), 14-23. doi:[10.1179/1351000215Y.0000000022](https://doi.org/10.1179/1351000215Y.0000000022)
8. Wong, G., Chua, S., Chadban, S. J., Clayton, P., Pilmore, H., Hughes, P. D., . . . Lim, W. H. (2016). Waiting time between failure of first graft and second kidney transplant and graft and patient survival. *Transplantation*, 100(8), 1767-1775. doi:[10.1097/TP.0000000000000953](https://doi.org/10.1097/TP.0000000000000953)
9. Allen, R., Pleass, H., Clayton, P. A., Woodroffe, C., & **Ferrari, P.** (2016). Outcomes of kidney paired donation transplants in relation to shipping and cold ischaemia time. *Transplant International*, 29(4), 425-431. doi:[10.1111/tri.12719](https://doi.org/10.1111/tri.12719)

10. Badve, S. V., Zhang, L., Coombes, J. S., Pascoe, E. M., Cass, A., Clarke, P., . . . Phoon, R. (2015). Association between serum alkaline phosphatase and primary resistance to erythropoiesis stimulating agents in chronic kidney disease: A secondary analysis of the HERO trial. *Canadian Journal of Kidney Health and Disease*, 2(1). doi:[10.1186/s40697-015-0066-5](https://doi.org/10.1186/s40697-015-0066-5)
11. Parfrey, P. S., Drüeke, T. B., Block, G. A., Correa-Rotter, R., Floege, J., Herzog, C. A., ...Donck, J. (2015). The effects of cinacalcet in older and younger patients on hemodialysis: The evaluation of cinacalcet HCL therapy to lower cardiovascular events (EVOLVE) trial. *Clinical Journal of the American Society of Nephrology*, 10(5), 791-799. doi:[10.2215/CJN.07730814](https://doi.org/10.2215/CJN.07730814) (contributor)
12. Moe, S. M., Chertow, G. M., Parfrey, P. S., Kubo, Y., Block, G. A., Correa-Rotter, R., . . . Tielemans, C. (2015). Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: The evaluation of cinacalcet HCL therapy to lower cardiovascular events (EVOLVE) trial. *Circulation*, 132(1), 27-39. doi:[10.1161/CIRCULATIONAHA.114.013876](https://doi.org/10.1161/CIRCULATIONAHA.114.013876) (contributor)
13. Johnson, D. W., Pascoe, E. M., Badve, S. V., Dalziel, K., Cass, A., Clarke, P., . . . Paul-Brent, P. A. (2014). A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: The handling erythropoietin resistance with oxpentifylline (HERO) trial. *American Journal of Kidney Diseases*, 65(1), 49-57. doi:[10.1053/j.ajkd.2014.06.020](https://doi.org/10.1053/j.ajkd.2014.06.020)
14. Graves, A., Yates, P., Hofmann, A. O., Farmer, S., & **Ferrari, P.** (2014). Predictors of perioperative blood transfusions in patients with chronic kidney disease undergoing elective knee and hip arthroplasty. *Nephrology*, 19(7), 404-409. doi:[10.1111/nep.12239](https://doi.org/10.1111/nep.12239)
15. Patankar, K., Low, R. S. T., Blakeway, D., & **Ferrari, P.** (2014). Comparison of computer tomographic volumetry versus nuclear split renal function to determine residual renal function after living kidney donation. *Acta Radiologica*, 55(6), 753-760. doi:[10.1177/0284185113504195](https://doi.org/10.1177/0284185113504195)
16. Nguyen, H. D., Wong, G., Howard, K., Claas, F. H. J., Craig, J. C., Fidler, S., . . . Lim, W. H. (2014). Modeling the benefits and costs of integrating an acceptable HLA mismatch allocation model for highly sensitized patients. *Transplantation*, 97(7), 769-774. doi:[10.1097/01.TP.0000438639.36838.ac](https://doi.org/10.1097/01.TP.0000438639.36838.ac)
17. Prezioso, D., Saita, A., Motta, M., Porena, M., Micheli, C., Illiano, E., . . . Russo, D. (2013). Serum fetuin-A and recurrent urolithiasis in young adults. *Archivio Italiano di Urologia e Andrologia*, 85(4), 180-183. doi:[10.4081/aiua.2013.4.180](https://doi.org/10.4081/aiua.2013.4.180)
18. Fidler, S., Swaminathan, R., Lim, W., **Ferrari, P.**, Witt, C., Christiansen, F. T., . . . Irish, A. B. (2013). Peri-operative third party red blood cell transfusion in renal transplantation and the risk of antibody-mediated rejection and graft loss. *Transplant Immunology*, 29(1-4), 22-27. doi:[10.1016/j.trim.2013.09.008](https://doi.org/10.1016/j.trim.2013.09.008)
19. **Ferrari, P.**, Hughes, P. D., Cohnney, S. J., Woodroffe, C., Fidler, S., & D'Orsogna, L. (2013). ABO-incompatible matching significantly enhances transplant rates in kidney paired donation. *Transplantation*, 96(9), 821-826. doi:[10.1097/TP.0b013e3182a01311](https://doi.org/10.1097/TP.0b013e3182a01311)
20. Maker, G. L., Siva, B., Batty, K. T., Trengove, R. D., **Ferrari, P.**, & Olynyk, J. K. (2013). Pharmacokinetics and safety of deferasirox in subjects with chronic kidney disease undergoing haemodialysis. *Nephrology*, 18(3), 188-193. doi:[10.1111/nep.12035](https://doi.org/10.1111/nep.12035)

21. Fidler, S. J., Irish, A. B., Lim, W., **Ferrari, P.**, Witt, C. S., & Christiansen, F. T. (2013). Pre-transplant donor specific anti-HLA antibody is associated with antibody-mediated rejection, progressive graft dysfunction and patient death. *Transplant Immunology*, 28(4), 148-153. doi:[10.1016/j.trim.2013.05.001](https://doi.org/10.1016/j.trim.2013.05.001)
22. Böhmig, G. A., Fidler, S., Christiansen, F. T., Fischer, G., & **Ferrari, P.** (2013). Transnational validation of the Australian algorithm for virtual crossmatch allocation in kidney paired donation. *Human Immunology*, 74(5), 500-505. doi:[10.1016/j.humimm.2013.01.029](https://doi.org/10.1016/j.humimm.2013.01.029)
23. **Ferrari, P.**, Fidler, S., Holdsworth, R., Woodroffe, C., Tassone, G., Watson, N., . . . D'Orsogna, L. (2012). High transplant rates of highly sensitized recipients with virtual crossmatching in kidney paired donation. *Transplantation*, 94(7), 744-749. doi:[10.1097/TP.0b013e3182612967](https://doi.org/10.1097/TP.0b013e3182612967)
24. **Ferrari, P.**, Fidler, S., Woodroffe, C., Tassone, G., & D'Orsogna, L. (2012). Comparison of time on the deceased donor kidney waitlist versus time on the kidney paired donation registry in the Australian program. *Transplant International*, 25(10), 1026-1031. doi:[10.1111/j.1432-2277.2012.01541.x](https://doi.org/10.1111/j.1432-2277.2012.01541.x)
25. Wu, C. J., Lin, K. C., Chen, S. T., Lai, W. T., Liu, C. P., Chiang, S. S., . . . **Ferrari, P.** (2011). Assessment of reasons for not intensifying antihypertensive treatment in the Taiwanese population. *Journal of the Formosan Medical Association*, 110(12), 768-774. doi:[10.1016/j.jfma.2011.11.007](https://doi.org/10.1016/j.jfma.2011.11.007)
26. Baigent, C., Landray, M. J., Reith, C., Emberson, J., Wheeler, D. C., Tomson, C., ... Collins, R. (2011). The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial. *The Lancet*, 377(9784), 2181-2192. doi:[10.1016/S0140-6736\(11\)60739-3](https://doi.org/10.1016/S0140-6736(11)60739-3) (contributor)
27. Wright, S., Steinwandel, U., & **Ferrari, P.** (2011). Citrate anticoagulation using ACD solution A during long-term haemodialysis. *Nephrology*, 16(4), 396-402. doi:[10.1111/j.1440-1797.2010.01421.x](https://doi.org/10.1111/j.1440-1797.2010.01421.x)
28. **Ferrari, P.**, Fidler, S., Wright, J., Woodroffe, C., Slater, P., Van Althuis-Jones, A., . . . Christiansen, F. T. (2011). Virtual crossmatch approach to maximize matching in paired kidney donation. *American Journal of Transplantation*, 11(2), 272-278. doi:[10.1111/j.1600-6143.2010.03313.x](https://doi.org/10.1111/j.1600-6143.2010.03313.x)
29. **Ferrari, P.**, Lim, W., Dent, H., & McDonald, S. P. (2011). Effect of donor-recipient age difference on graft function and survival in live-donor kidney transplantation. *Nephrology Dialysis Transplantation*, 26(2), 702-708. doi:[10.1093/ndt/gfq383](https://doi.org/10.1093/ndt/gfq383)
30. **Ferrari, P.**, Kulkarni, H., Dheda, S., Betti, S., Harrison, C., St Pierre, T. G., & Olynyk, J. K. (2011). Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease. *Clinical Journal of the American Society of Nephrology*, 6(1), 77-83. doi:[10.2215/CJN.04190510](https://doi.org/10.2215/CJN.04190510)
31. Campbell, S., Hawley, C., Irish, A., Hutchison, B., Walker, R., Butcher, B. E., & **Ferrari, P.** (2010). Pre-transplant pharmacokinetic profiling and tacrolimus requirements post-transplant. *Nephrology (Carlton, Vic.)*, 15(7), 714-719.
32. Baigent, C., Landray, M., Reith, C., Dasgupta, T., Emberson, J., Herrington, W., ... Zhu, W. (2010). Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. *American Heart Journal*, 160(5). doi:[10.1016/j.ahj.2010.08.012](https://doi.org/10.1016/j.ahj.2010.08.012) (contributor)

33. **Ferrari, P.**, Mallon, D., Trinder, D., & Olynyk, J. K. (2010). Pentoxifylline improves haemoglobin and interleukin-6 levels in chronic kidney disease. *Nephrology*, *15*(3), 344-349. doi:[10.1111/j.1440-1797.2009.01203.x](https://doi.org/10.1111/j.1440-1797.2009.01203.x)
34. Mehta, A., Beck, M., Elliott, P., Giugliani, R., Linhart, A., Sunder-Plassmann, G., . . . Fabry Outcome Survey investigators. (2009). Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data. *Lancet*, *374*(9706), 1986-1996. doi:[10.1016/S0140-6736\(09\)61493-8](https://doi.org/10.1016/S0140-6736(09)61493-8) (contributor)
35. Boudville, N., Salama, M., Jeffrey, G. P., & **Ferrari, P.** (2009). The inaccuracy of cystatin C and creatinine-based equations in predicting GFR in orthotopic liver transplant recipients. *Nephrology Dialysis Transplantation*, *24*(9), 2926-2930. doi:[10.1093/ndt/gfp255](https://doi.org/10.1093/ndt/gfp255)
36. Makarounas-Kirchmann, K., Glover-Koudounas, S., & **Ferrari, P.** (2009). Results of a meta-analysis comparing the tolerability of lercanidipine and other dihydropyridine calcium channel blockers. *Clinical Therapeutics*, *31*(8), 1652-1663. doi:[10.1016/j.clinthera.2009.08.010](https://doi.org/10.1016/j.clinthera.2009.08.010)
37. **Ferrari, P.**, Singer, R., Agarwal, A., Hurn, A., Townsend, M. A., & Chubb, P. (2009). Serum phosphate is an important determinant of corrected serum calcium in end-stage kidney disease. *Nephrology*, *14*(4), 383-388. doi:[10.1111/j.1440-1797.2009.01121.x](https://doi.org/10.1111/j.1440-1797.2009.01121.x)
38. **Ferrari, P.**, Xiao, J., Ukich, A., & Irish, A. (2009). Estimation of glomerular filtration rate: Does haemoglobin discriminate between ageing and true CKD. *Nephrology Dialysis Transplantation*, *24*(6), 1828-1833. doi:[10.1093/ndt/gfn738](https://doi.org/10.1093/ndt/gfn738)
39. **Ferrari, P.** (2009). Reasons for therapeutic inertia when managing hypertension in clinical practice in non-Western countries. *Journal of Human Hypertension*, *23*(3), 151-159. doi:[10.1038/jhh.2008.117](https://doi.org/10.1038/jhh.2008.117)
40. Johnson, D. W., Hawley, C. M., Rosser, B., Beller, E., Thompson, C., Fassett, R. G., . . . Cass, A. (2008). Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: A randomized controlled trial. *BMC Nephrology*, *9*(1). doi:[10.1186/1471-2369-9-8](https://doi.org/10.1186/1471-2369-9-8)
41. Salama, M., Boudville, N., Speers, D., Jeffrey, G. P., & **Ferrari, P.** (2008). Decline in native kidney function in liver transplant recipients is not associated with BK virus infection. *Liver Transplantation*, *14*(12), 1787-1792. doi:[10.1002/lt.21627](https://doi.org/10.1002/lt.21627)
42. Singer, R., Rhodes, H. C., Chin, G., Kulkarni, H., & **Ferrari, P.** (2008). High prevalence of ascorbate deficiency in an Australian peritoneal dialysis population. *Nephrology*, *13*(1), 17-22. doi:[10.1111/j.1440-1797.2007.00857.x](https://doi.org/10.1111/j.1440-1797.2007.00857.x)
43. Atanasov, A. G., Ignatova, I. D., Nashev, L. G., Dick, B., **Ferrari, P.**, Frey, F. J., & Odermatt, A. (2007). Impaired protein stability of 11 β -hydroxysteroid dehydrogenase type 2: A novel mechanism of apparent mineralocorticoid excess. *Journal of the American Society of Nephrology*, *18*(4), 1262-1270. doi:[10.1681/ASN.2006111235](https://doi.org/10.1681/ASN.2006111235)
44. Demant, A. W., Kocovic, L., Henschkowski, J., Siebenrock, K. A., **Ferrari, P.**, Steinbach, L. S., & Anderson, S. E. (2007). Hip pain in renal transplant recipients: Symptomatic gluteus minimus and gluteus medius tendon abnormality as an alternative MRI diagnosis to avascular necrosis. *American Journal of Roentgenology*, *188*(2), 515-519. doi:[10.2214/AJR.05.1097](https://doi.org/10.2214/AJR.05.1097)
45. Morineau, G., Sulmont, V., Salomon, R., Fiquet-Kempf, B., JeunemaÓtre, X., Nicod, J., & **Ferrari, P.** (2006). Apparent mineralocorticoid excess: Report of six new cases and extensive personal experience. *Journal of the American Society of Nephrology*, *17*(11), 3176-3184. doi:[10.1681/ASN.2006060570](https://doi.org/10.1681/ASN.2006060570)

46. Casal, A. J., Sinclair, V. J. P., Capponi, A. M., Nicod, J., Huynh-Do, U., & **Ferrari, P.** (2006). A novel mutation in the steroidogenic acute regulatory protein gene promoter leading to reduced promoter activity. *Journal of Molecular Endocrinology*, 37(1), 71-80. doi:[10.1677/jme.1.02082](https://doi.org/10.1677/jme.1.02082)
47. **Ferrari, P.**, Kim, S. K., Wu, C. J., Pham, N. V., Ageev, F., Hermosillo, L. D., & Esper, R. (2006). Aim, design and methods of the "reasons for not intensifying antihypertensive treatment" (RIAT): An international registry in essential hypertension. *Journal of Human Hypertension*, 20(1), 31-36. doi:[10.1038/sj.jhh.1001937](https://doi.org/10.1038/sj.jhh.1001937)
48. Orth, S. R., Schroeder, T., Ritz, E., & **Ferrari, P.** (2005). Effects of smoking on renal function in patients with type 1 and type 2 diabetes mellitus. *Nephrology Dialysis Transplantation*, 20(11), 2414-2419. doi:[10.1093/ndt/gfi022](https://doi.org/10.1093/ndt/gfi022)
49. Strojek, K., Nicod, J., **Ferrari, P.**, Grzeszczak, W., Gorska, J., Dick, B., . . . Ritz, E. (2005). Salt-sensitive blood pressure - An intermediate phenotype predisposing to diabetic nephropathy?. *Nephrology Dialysis Transplantation*, 20(10), 2113-2119. doi:[10.1093/ndt/gfh873](https://doi.org/10.1093/ndt/gfh873)
50. Uehlinger, D. E., Jakob, S. M., **Ferrari, P.**, Eichelberger, M., Huynh-Do, U., Marti, H. P., . . . Frey, F. J. (2005). Comparison of continuous and intermittent renal replacement therapy for acute renal failure. *Nephrology Dialysis Transplantation*, 20(8), 1630-1637. doi:[10.1093/ndt/gfh880](https://doi.org/10.1093/ndt/gfh880)
51. Gabutti, L., Machacek, M., Marone, C., & **Ferrari, P.** (2005). Predicting intradialytic hypotension from experience, statistical models and artificial neural networks. *Journal of Nephrology*, 18(4), 409-416. <https://www.ncbi.nlm.nih.gov/pubmed/16245245>
52. Ganapathipillai, S., Laval, G., Hoffmann, I. S., Castejon, A. M., Nicod, J., Dick, B., . . . **Ferrari, P.** (2005). CYP11B2-CYP11B1 haplotypes associated with decreased 11 β -hydroxylase activity. *Journal of Clinical Endocrinology and Metabolism*, 90(2), 1220-1225. doi:[10.1210/jc.2004-1031](https://doi.org/10.1210/jc.2004-1031)
53. Pechère-Bertschi, A., Greminger, P., Hess, L., Philippe, J., & **Ferrari, P.** (2005). Swiss Hypertension and Risk Factor Program (SHARP): Cardiovascular risk factors management in patients with type 2 diabetes in Switzerland. *Blood Pressure*, 14(6), 337-344. doi:[10.1080/08037050500340018](https://doi.org/10.1080/08037050500340018)
54. Shankar, R. R., **Ferrari, P.**, Dick, B., Ambrosius, W. T., Eckert, G. J., & Pratt, J. H. (2005). Activity of 11 β -hydroxysteroid dehydrogenase type 2 in normotensive blacks and whites. *Ethnicity and Disease*, 15(3), 407-410.
55. Trochen, N., Ganapathipillai, S., **Ferrari, P.**, Frey, B. M., & Frey, F. J. (2004). Low prevalence of nonconservative mutations of serum and glucocorticoid-regulated kinase (SGK1) gene in hypertensive and renal patients. *Nephrology Dialysis Transplantation*, 19(10), 2499-2504. doi:[10.1093/ndt/gfh417](https://doi.org/10.1093/ndt/gfh417)
56. **Ferrari, P.**, Hess, L., Pechere-Bertschi, A., Muggli, F., & Burnier, M. (2004). Reasons for not intensifying antihypertensive treatment (RIAT): A primary care antihypertensive intervention study. *Journal of Hypertension*, 22(6), 1221-1229. doi:[10.1097/00004872-200406000-00024](https://doi.org/10.1097/00004872-200406000-00024)
57. Nicod, J., Dick, B., Frey, F. J., & **Ferrari, P.** (2004). Mutation analysis of CYP11B1 and CYP11B2 in patients with increased 18-hydroxycortisol production. *Molecular and Cellular Endocrinology*, 214(1-2), 167-174. doi:[10.1016/j.mce.2003.10.056](https://doi.org/10.1016/j.mce.2003.10.056)

58. **Ferrari, P.**, Shaw, S. G., Nicod, J., Saner, E., & Nussberger, J. (2004). Active renin versus plasma renin activity to define aldosterone-to-renin ratio for primary aldosteronism. *Journal of Hypertension*, 22(2), 377-381. doi:[10.1097/00004872-200402000-00023](https://doi.org/10.1097/00004872-200402000-00023)
59. Lods, N., **Ferrari, P.**, Frey, F. J., Kappeler, A., Berthier, C., Vogt, B., & Marti, H. P. (2003). Angiotensin-Converting Enzyme Inhibition but not Angiotensin II Receptor Blockade Regulates Matrix Metalloproteinase Activity in Patients with Glomerulonephritis. *Journal of the American Society of Nephrology*, 14(11), 2861-2872. doi:[10.1097/01.ASN.0000092789.67966.5C](https://doi.org/10.1097/01.ASN.0000092789.67966.5C)
60. Nicod, J., Bruhin, D., Auer, L., Vogt, B., Frey, F. J., & **Ferrari, P.** (2003). A biallelic gene polymorphism of CYP11B2 predicts increased aldosterone to renin ratio in selected hypertensive patients. *Journal of Clinical Endocrinology and Metabolism*, 88(6), 2495-2500. doi:[10.1210/jc.2002-021598](https://doi.org/10.1210/jc.2002-021598)
61. Heiniger, C. D., Kostadinova, R. M., Rochat, M. K., Serra, A., **Ferrari, P.**, Dick, B., . . . Frey, F. J. (2003). Hypoxia causes down-regulation of 11 beta-hydroxysteroid dehydrogenase type 2 by induction of Egr-1. *The FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 17(8), 917-919.
62. Wagner, M., Cadetg, P., Ruf, R., Mazzucchelli, L., **Ferrari, P.**, & Redaelli, C. A. (2003). Heme oxygenase-1 attenuates ischemia/reperfusion-induced apoptosis and improves survival in rat renal allografts. *Kidney International*, 63(4), 1564-1573. doi:[10.1046/j.1523-1755.2003.00897.x](https://doi.org/10.1046/j.1523-1755.2003.00897.x)
63. Mazzola, B. L., Vannini, S. D. P., Truttmann, A. C., Von Vigier, R. O., Wermuth, B., **Ferrari, P.**, & Bianchetti, M. G. (2003). Long-term calcineurin inhibition and magnesium balance after renal transplantation. *Transplant International*, 16(2), 76-81. doi:[10.1111/j.1432-2277.2003.tb00267.x](https://doi.org/10.1111/j.1432-2277.2003.tb00267.x)
64. Orth, S. R., Odoni, G., Karkoszka, H., Ogata, H., Viedt, C., Amann, K., . . . Ritz, E. (2003). Combination treatment with an ET<inf>A</inf>-receptor blocker and an ACE inhibitor is not superior to the respective monotherapies in attenuating chronic transplant vasculopathy in different aorta allotransplantation rat models. *Nephrology Dialysis Transplantation*, 18(1), 62-69. doi:[10.1093/ndt/18.1.62](https://doi.org/10.1093/ndt/18.1.62)
65. **Ferrari, P.**, Schroeder, V., Anderson, S., Kocovic, L., Vogt, B., Schiesser, D., . . . Kohler, H. P. (2002). Association of plasminogen activator inhibitor-1 genotype with avascular osteonecrosis in steroid-treated renal allograft recipients. *Transplantation*, 74(8), 1147-1152. doi:[10.1097/00007890-200210270-00016](https://doi.org/10.1097/00007890-200210270-00016)
66. **Ferrari, P.**, Bianchetti, M. G., Sansonnens, A., & Frey, F. J. (2002). Modulation of renal calcium handling by 11 β -hydroxysteroid dehydrogenase type 2. *Journal of the American Society of Nephrology*, 13(10), 2540-2546. doi:[10.1097/01.ASN.0000028640.78526.0F](https://doi.org/10.1097/01.ASN.0000028640.78526.0F)
67. Schumacher, M., Frey, F. J., Montani, J. P., Dick, B., Frey, B. M., & **Ferrari, P.** (2002). Salt-sensitivity of blood pressure and decreased 11 β hydroxysteroid dehydrogenase type 2 activity after renal transplantation. *Transplantation*, 74(1), 66-72. doi:[10.1097/00007890-200207150-00012](https://doi.org/10.1097/00007890-200207150-00012)
68. Nicod, J., Frey, B. M., Frey, F. J., & **Ferrari, P.** (2002). Role of the α -adducin genotype on renal disease progression. *Kidney International*, 61(4), 1270-1275. doi:[10.1046/j.1523-1755.2002.00275.x](https://doi.org/10.1046/j.1523-1755.2002.00275.x)
69. Nicod, J., Richard, A., Frey, F. J., & **Ferrari, P.** (2002). Recipient RAS gene variants and renal allograft function. *Transplantation*, 73(6), 960-965. doi:[10.1097/00007890-200203270-00023](https://doi.org/10.1097/00007890-200203270-00023)

70. Lu, J., Pfister, M., **Ferrari, P.**, Chen, G., & Sheiner, L. (2002). Pharmacokinetic-pharmacodynamic modelling of magnesium plasma concentration and blood pressure in preeclamptic women. *Clinical Pharmacokinetics*, 41(13), 1105-1113. doi:[10.2165/00003088-200241130-00007](https://doi.org/10.2165/00003088-200241130-00007)
71. Serra, A., Uehlinger, D. E., **Ferrari, P.**, Dick, B., Frey, B. M., Frey, F. J., & Vogt, B. (2002). Glycyrrhetic acid decreases plasma potassium concentrations in patients with anuria. *Journal of the American Society of Nephrology*, 13(1), 191-196.
72. **Ferrari, P.**, Marti, H. P., Pfister, M., & Frey, F. J. (2002). Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade. *Journal of Hypertension*, 20(1), 125-130. doi:[10.1097/00004872-200201000-00018](https://doi.org/10.1097/00004872-200201000-00018)
73. Vogt, B., **Ferrari, P.**, Sch[^]nholzer, C., Marti, H. P., Mohaupt, M., Wiederkehr, M., . . . Frey, F. J. (2001). Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. *American Journal of Medicine*, 111(9), 692-698. doi:[10.1016/S0002-9343\(01\)00983-4](https://doi.org/10.1016/S0002-9343(01)00983-4)
74. **Ferrari, P.**, Sansonnens, A., Dick, B., & Frey, F. J. (2001). In vivo 11 β -HSD-2 activity: Variability, salt-sensitivity, and effect of licorice. *Hypertension*, 38(6), 1330-1336. doi:[10.1161/hy1101.096112](https://doi.org/10.1161/hy1101.096112)
75. Lovati, E., Richard, A., Frey, B. M., Frey, F. J., & **Ferrari, P.** (2001). Genetic polymorphisms of the renin-angiotensin-aldosterone system in end-stage renal disease. *Kidney International*, 60(1), 46-54. doi:[10.1046/j.1523-1755.2001.00769.x](https://doi.org/10.1046/j.1523-1755.2001.00769.x)
76. Odermatt, A., Dick, B., Arnold, P., Zaehner, T., Plueschke, V., Deregibus, M. N., . . . **Ferrari, P.** (2001). A mutation in the cofactor-binding domain of 11 β -hydroxysteroid dehydrogenase type 2 associated with mineralocorticoid hypertension. *Journal of Clinical Endocrinology and Metabolism*, 86(3), 1247-1252. doi:[10.1210/jc.86.3.1247](https://doi.org/10.1210/jc.86.3.1247)
77. Odermatt, A., Dick, B., Arnold, P., Zaehner, T., Plueschke, V., Deregibus, M. N., . . . **Ferrari, P.** (2001). A mutation in the cofactor-binding domain of 11beta-hydroxysteroid dehydrogenase type 2 associated with mineralocorticoid hypertension. *J Clin Endocrinol Metab*, 86(3), 1247-1252. doi:[10.1210/jcem.86.3.7334](https://doi.org/10.1210/jcem.86.3.7334)
78. Zaehner, T., Plueshke, V., Frey, B. M., Frey, F. J., & **Ferrari, P.** (2000). Structural analysis of the 11 β -hydroxysteroid dehydrogenase type 2 gene in end-stage renal disease. *Kidney International*, 58(4), 1413-1419. doi:[10.1046/j.1523-1755.2000.00303.x](https://doi.org/10.1046/j.1523-1755.2000.00303.x)
79. **Ferrari, P.**, Lovati, E., & Frey, F. J. (2000). The role of the 11 β -hydroxysteroid dehydrogenase type 2 in human hypertension. *Journal of Hypertension*, 18(3), 241-248. doi:[10.1097/00004872-200018030-00001](https://doi.org/10.1097/00004872-200018030-00001)
80. Lovati, E., **Ferrari, P.**, Dick, B., Jostarndt, K., Frey, B. M., Frey, F. J., . . . Sharma, A. M. (1999). Molecular basis of human salt sensitivity: The role of the 11 β -hydroxysteroid dehydrogenase type 2. *Journal of Clinical Endocrinology and Metabolism*, 84(10), 3745-3749. doi:10.1210/jcem.84.10.6098
81. Vannini, S. D. P., Mazzola, B. L., Rodoni, L., Truttmann, A. C., Wermuth, B., Bianchetti, M. G., & **Ferrari, P.** (1999). Permanently reduced plasma ionized magnesium among renal transplant recipients on cyclosporine. *Transplant International*, 12(4), 244-249. doi:[10.1007/s001470050217](https://doi.org/10.1007/s001470050217)

82. **Ferrari, P.**, Siccoli, M. M., Fontana, M. J. I., & Bianchetti, M. G. (1999). Abnormalities in insulin sensitivity, vascular resistance and erythrocyte cation transport are independent genetic traits in familial hypertension. *Blood Pressure*, 8(2), 102-109. doi:[10.1080/080370599438275](https://doi.org/10.1080/080370599438275)
83. Rogoff, D., Smolenicka, Z., Bergad, I., Vallejo, G., Barontini, M., Heinrich, J. J., & **Ferrari, P.** (1998). The codon 213 of the 11 β -hydroxysteroid dehydrogenase type 2 gene is a hot spot for mutations in apparent mineralocorticoid excess. *Journal of Clinical Endocrinology and Metabolism*, 83(12), 4391-4393. doi:[10.1210/jc.83.12.4391](https://doi.org/10.1210/jc.83.12.4391)
84. Teuscher, A. U., Lerch, M., Shaw, S., Pacini, G., **Ferrari, P.**, & Weidmann, P. (1998). Endothelin-1 infusion inhibits plasma insulin responsiveness in normal men. *Journal of Hypertension*, 16(9), 1279-1284. doi:[10.1097/00004872-199816090-00009](https://doi.org/10.1097/00004872-199816090-00009)
85. Laederach-Hofmann, K., Weidmann, P., & **Ferrari, P.** (1999). Hypovolemia contributes to the pathogenesis of orthostatic hypotension in patients with diabetes mellitus. *American Journal of Medicine*, 106(1), 50-58. doi:[10.1016/S0002-9343\(98\)00367-2](https://doi.org/10.1016/S0002-9343(98)00367-2)
86. Wilson, R. C., Dave-Sharma, S., Wei, J. Q., Obeyesekere, V. R., Li, K., **Ferrari, P.**, . . . New, M. I. (1998). A genetic defect resulting in mild low-renin hypertension. *Proceedings of the National Academy of Sciences of the United States of America*, 95(17), 10200-10205. doi:[10.1073/pnas.95.17.10200](https://doi.org/10.1073/pnas.95.17.10200)
87. Ferrandi, M., Manunta, P., Rivera, R., Bianchi, G., & **Ferrari, P.** (1998). Role of the ouabain-like factor and Na-K pump in rat and human genetic hypertension. In *Clinical and Experimental Hypertension* Vol. 20 (pp. 629-639). doi:[10.3109/10641969809053241](https://doi.org/10.3109/10641969809053241)
88. Smolenicka, Z., Bach, E., Schaer, A., Liechti-Gallati, S., Frey, B. M., Frey, F. J., & **Ferrari, P.** (1998). A new polymorphic restriction site in the human 11 β -hydroxysteroid dehydrogenase type 2 gene. *Journal of Clinical Endocrinology and Metabolism*, 83(5), 1814-1817. doi:[10.1210/jc.83.5.1814](https://doi.org/10.1210/jc.83.5.1814)
89. **Ferrari, P.**, Torielli, L., Ferrandi, M., Padoani, G., Duzzi, L., Florio, M., . . . Bianchi, G. (1998). PST2238: A new antihypertensive compound that antagonizes the long-term pressor effect of ouabain. *Journal of Pharmacology and Experimental Therapeutics*, 285(1), 83-94. [PMID 9535997](https://pubmed.ncbi.nlm.nih.gov/9535997/)
90. Obeyesekere, V. R., Li, K. X. Z., **Ferrari, P.**, & Krozowski, Z. (1997). Truncation of the N- and C-terminal regions of the human 11 β -hydroxysteroid dehydrogenase type 2 enzyme and effects on solubility and bidirectional enzyme activity. *Molecular and Cellular Endocrinology*, 131(2), 173-182. doi:[10.1016/S0303-7207\(97\)00106-8](https://doi.org/10.1016/S0303-7207(97)00106-8)
91. Li, K. X. Z., Obeyesekere, V. R., Krozowski, Z. S., & **Ferrari, P.** (1997). Oxoreductase and dehydrogenase activities of the human and rat 11 β -hydroxysteroid dehydrogenase type 2 enzyme. *Endocrinology*, 138(7), 2948-2952. doi:[10.1210/endo.138.7.5232](https://doi.org/10.1210/endo.138.7.5232)
92. Krozowski, Z. S., Stewart, P. M., Obeyesekere, V. R., Li, K., & **Ferrari, P.** (1997). Mutations in the 11 β -hydroxysteroid dehydrogenase type II enzyme associated with hypertension and possibly stillbirth. *Clinical and Experimental Hypertension*, 19(5-6), 519-529. doi:[10.3109/10641969709083166](https://doi.org/10.3109/10641969709083166)
93. **Ferrari, P.**, Smith, R. E., Funder, J. W., & Krozowski, Z. S. (1996). Substrate and inhibitor specificity of the cloned human 11 β -hydroxysteroid dehydrogenase type 2 isoform. *American Journal of Physiology - Endocrinology and Metabolism*, 270(5). doi:[10.1152/ajpendo.1996.270.5.E900](https://doi.org/10.1152/ajpendo.1996.270.5.E900)

94. Wissmann, C., Frey, F. J., **Ferrari, P.**, & Uehlinger, D. E. (1996). Acute cyclosporine-induced nephrotoxicity in renal transplant recipients: The role of the transplanted kidney. *Journal of the American Society of Nephrology*, 7(12), 2677-2681.
95. Li, K. X. Z., Smith, R. E., **Ferrari, P.**, Funder, J. W., & Krozowski, Z. S. (1996). Rat 11 β -hydroxysteroid dehydrogenase type 2 enzyme is expressed at low levels in the placenta and is modulated by adrenal steroids in the kidney. *Molecular and Cellular Endocrinology*, 120(1), 67-75. doi:[10.1016/0303-7207\(96\)03822-1](https://doi.org/10.1016/0303-7207(96)03822-1)
96. Tripodi, G., Valtorta, F., Torielli, L., Chierigatti, E., Salardi, S., Trusolino, L., . . . Bianchi, G. (1996). Hypertension-associated point mutations in the adducin alpha and beta subunits affect actin cytoskeleton and ion transport. *J Clin Invest*, 97(12), 2815-2822. doi:[10.1172/JCI118737](https://doi.org/10.1172/JCI118737)
97. **Ferrari, P.**, Obeyesekere, V. R., Li, K., Wilson, R. C., New, M. I., Funder, J. W., & Krozowski, Z. S. (1996). Point mutations abolish 11 β -hydroxysteroid dehydrogenase type II activity in three families with the congenital syndrome of apparent mineralocorticoid excess. *Molecular and Cellular Endocrinology*, 119(1), 21-24. doi:[10.1016/0303-7207\(96\)03787-2](https://doi.org/10.1016/0303-7207(96)03787-2)
98. **Ferrari, P.**, Smith, R. E., Funder, J. W., & Krozowski, Z. S. (1996). Substrate and inhibitor specificity of the cloned human 11 beta-hydroxysteroid dehydrogenase type 2 isoform. *Am J Physiol*, 270(5 Pt 1), E900-E904. doi:[10.1152/ajpendo.1996.270.5.E900](https://doi.org/10.1152/ajpendo.1996.270.5.E900)
99. **Ferrari, P.**, Obeyesekere, V. R., Li, K., Andrews, R. K., & Krozowski, Z. S. (1996). The 11 β -hydroxysteroid dehydrogenase type II enzyme: Biochemical consequences of the congenital R337C mutation. *Steroids*, 61(4), 197-200. doi:[10.1016/0039-128X\(96\)00013-X](https://doi.org/10.1016/0039-128X(96)00013-X)
100. **Ferrari, P.**, Gadiant, G., Cozzio, A., Shaw, S., & Weidmann, P. (1996). Reduced plasma cyclic GMP but normal renal responses to atrial natriuretic factor in pre-hypertension. *Blood Pressure*, 5(1), 16-26. doi:[10.3109/08037059609062102](https://doi.org/10.3109/08037059609062102)
101. Obeyesekere, V. R., **Ferrari, P.**, Andrews, R. K., Wilson, R. C., New, M. I., Funder, J. W., & Krozowski, Z. S. (1995). The R337C mutation generates a high Km 11 β -hydroxysteroid dehydrogenase type II enzyme in a family with apparent mineralocorticoid excess. *Journal of Clinical Endocrinology and Metabolism*, 80(11), 3381-3383. doi:[10.1210/jcem.80.11.7593456](https://doi.org/10.1210/jcem.80.11.7593456)
102. Böhlen, L., **Ferrari, P.**, Papiri, M., Allemann, Y., Shaw, S., & Weidmann, P. (1994). Atrial natriuretic factor increases in response to an acute glucose load. *Journal of Hypertension*, 12(7), 803-807. PMID [7963509](https://pubmed.ncbi.nlm.nih.gov/7963509/)
103. **Ferrari, P.**, Weidmann, P., Riesen, W. F., Martius, F., Luban, S., Pasotti, E., . . . Wunderlin, R. (1993). Pravastatin in the treatment of primary hypercholesterolemia: A Swiss multicentre study. *Schweizerische Medizinische Wochenschrift*, 123(37), 1736-1741. PMID [8211024](https://pubmed.ncbi.nlm.nih.gov/8211024/)
104. Allemann, Y., Horber, F. F., Colombo, M., **Ferrari, P.**, Shaw, S., Jaeger, P., & Weidmann, P. (1993). Insulin sensitivity and body fat distribution in normotensive offspring of hypertensive parents. *The Lancet*, 341(8841), 327-331. doi:[10.1016/0140-6736\(93\)90135-4](https://doi.org/10.1016/0140-6736(93)90135-4)
105. de Courten, M., **Ferrari, P.**, Schneider, M., Böhlen, L., Shaw, S., Riesen, W., . . . Weidmann, P. (1993). Lack of effect of long-term amlodipine on insulin sensitivity and plasma insulin in obese patients with essential hypertension. *European Journal of Clinical Pharmacology*, 44(5), 457-462. doi:[10.1007/BF00315543](https://doi.org/10.1007/BF00315543)

106. Allemann, Y., Aeschbacher, B., Zwysig, P., **Ferrari, P.**, Hopf, M., Shaw, S., . . . Weidmann, P. (1992). Left ventricular structure and determinants in normotensive offspring of essential hypertensive parents. *Journal of Hypertension*, *10*(10), 1257-1264. doi:[10.1097/00004872-199210000-00021](https://doi.org/10.1097/00004872-199210000-00021)
107. **Ferrari, P.**, Ostini, E., Allemann, Y., de Courten, M., & Weidmann, P. (1992). [Diagnostic value of ambulatory daily blood pressure profile: comparison with measurements performed by a laboratory technician]. *Schweiz Med Wochenschr*, *122*(36), 1317-1324. [PMID 1411388](https://pubmed.ncbi.nlm.nih.gov/1411388/)
108. **Ferrari, P.**, Travaglini, M., Schild, C., Allemann, Y., Shaw, S., & Weidmann, P. (1992). Enhanced blood pressure response to mineralocorticoid stimulation in normotensive members of hypertensive families. *Blood Pressure*, *1*(2), 86-91. doi:[10.3109/08037059209077498](https://doi.org/10.3109/08037059209077498)
109. Parenti, P., **Ferrari, P.**, Ferrandi, M., Hanozet, G. M., & Bianchi, G. (1992). Effect of amiloride analogues on sodium transport in renal brush border membrane vesicles from milan hypertensive rats. *Biochemical and Biophysical Research Communications*, *183*(1), 55-61. doi:[10.1016/0006-291X\(92\)91608-S](https://doi.org/10.1016/0006-291X(92)91608-S)
110. Blumberg, A., Weidmann, P., & **Ferrari, P.** (1992). Effect of prolonged bicarbonate administration on plasma potassium in terminal renal failure. *Kidney International*, *41*(2), 369-374. doi:[10.1038/ki.1992.51](https://doi.org/10.1038/ki.1992.51)
111. Ferrier, C., **Ferrari, P.**, Weidmann, P., Keller, U., Beretta-Piccoli, C., & Riesen, W. F. (1992). Swiss Hypertension Treatment Programme with Verapamil and/or Enalapril in Diabetic Patients. *Drugs*, *44*(1), 74-84. doi:[10.2165/00003495-199200441-00014](https://doi.org/10.2165/00003495-199200441-00014)
112. **Ferrari, P.**, Shaw, S., Riesen, W., & Weidmann, P. (1992). Plasma insulin during physiological and pathophysiological changes in atrial natriuretic factor. *European Journal of Clinical Pharmacology*, *42*(4), 453-455. doi:[10.1007/BF00280135](https://doi.org/10.1007/BF00280135)
113. Allemann, Y., Baumann, S., Jost, M., **Ferrari, P.**, Shaw, S., Riesen, W., & Weidmann, P. (1992). Insulin sensitivity in normotensive subjects during angiotensin converting enzyme inhibition with fosinopril. *European Journal of Clinical Pharmacology*, *42*(3), 275-280. doi:[10.1007/BF00266348](https://doi.org/10.1007/BF00266348)
114. Pfenninger, J., Shaw, S., **Ferrari, P.**, & Weidmann, P. (1991). Atrial natriuretic factor after cardiac surgery with cardiopulmonary bypass in children. *Critical Care Medicine*, *19*(12), 1497-1502. doi:[10.1097/00003246-199112000-00010](https://doi.org/10.1097/00003246-199112000-00010)
115. **Ferrari, P.**, Weidmann, P., Shaw, S., Giachino, D., Riesen, W., Allemann, Y., & Heynen, G. (1991). Altered insulin sensitivity, hyperinsulinemia, and dyslipidemia in individuals with a hypertensive parent. *The American Journal of Medicine*, *91*(6), 589-596. doi:[10.1016/0002-9343\(91\)90211-F](https://doi.org/10.1016/0002-9343(91)90211-F)
116. Ferrier, C., **Ferrari, P.**, Weidmann, P., Keller, U., Beretta-Piccoli, C., & Riesen, W. F. (1991). Antihypertensive therapy with Ca-Antagonist verapamil and/or ACE inhibitor enalapril in NIDDM patients. *Diabetes Care*, *14*(10), 911-914. doi:[10.2337/diacare.14.10.911](https://doi.org/10.2337/diacare.14.10.911)
117. Parenti, P., Villa, M., Hanozet, G. M., Ferrandi, M., & **Ferrari, P.** (1991). Increased Na pump activity in the kidney cortex of the Milan hypertensive rat strain. *FEBS Letters*, *290*(1-2), 200-204. doi:[10.1016/0014-5793\(91\)81259-B](https://doi.org/10.1016/0014-5793(91)81259-B)
118. **Ferrari, P.**, Alleman, Y., Shaw, S., Riesen, W., & Weidmann, P. (1991). Reproducibility of insulin sensitivity measured by the minimal model method. *Diabetologia*, *34*(7), 527-530. doi:[10.1007/BF00403291](https://doi.org/10.1007/BF00403291)

119. **Ferrari, P.**, Rosman, J., Neuner, N., Shaw, S., Riesen, W., & Weidmann, P. (1991). Postsynaptic α 1-blockade with terazosin does not modify insulin sensitivity in nonobese normotensive subjects. *Journal of Cardiovascular Pharmacology*, 18(1), 106-110. doi:[10.1097/00005344-199107000-00014](https://doi.org/10.1097/00005344-199107000-00014)
120. **Ferrari, P.**, Giachino, D., Weidmann, P., Shaw, S., Riesen, W., Neuner, N., . . . Heynen, G. (1991). Unaltered insulin sensitivity during calcium channel blockade with amlodipine. *European Journal of Clinical Pharmacology*, 41(2), 109-113. doi:[10.1007/BF00265901](https://doi.org/10.1007/BF00265901)
121. Saxenhofer, H., Raselli, A., Weidmann, P., Forssmann, W. G., Bub, A., **Ferrari, P.**, & Shaw, S. G. (1990). Urodilatin, a natriuretic factor from kidneys, can modify renal and cardiovascular function in men.. *Am J Physiol*, 259(5 Pt 2), F832-F838. doi:[10.1152/ajprenal.1990.259.5.F832](https://doi.org/10.1152/ajprenal.1990.259.5.F832)
122. **Ferrari, P.**, Weidmann, P., Ferrier, C., Dietler, R., Hollmann, R., Jan Pise, R., . . . Shaw, S. (1990). Dysregulation of Atrial Natriuretic Factor in Hypertension-Prone Man. *Journal of Clinical Endocrinology and Metabolism*, 71(4), 944-951. doi:[10.1210/jcem-71-4-944](https://doi.org/10.1210/jcem-71-4-944)
123. Weidmann, P., Schohn, D. C., Riesen, W., Jahn, H. A., **Ferrari, P.**, Shaw, S. G., & Beretta-Piccoli, C. (1990). Association between sympathetic activity and the atherogenic serum cholesterol fraction. *Klinische Wochenschrift*, 68(5), 269-276. doi:[10.1007/BF02116055](https://doi.org/10.1007/BF02116055)
124. Saxenhofer, H., Raselli, A., Weidmann, P., Forssmann, W. G., Bub, A., **Ferrari, P.**, & Shaw, S. G. (1990). Urodilatin, a natriuretic factor from kidneys, can modify renal and cardiovascular function in men. *American Journal of Physiology - Renal Fluid and Electrolyte Physiology*, 259(5 28-5). 10.1152/ajprenal.1990.259.5.F832
125. **Ferrari, P.**, Ferrier, C. P., Francini, L., Saxenhofer, H., Shaw, S., & Weidmann, P. (1990). Atrial natriuretic factor and autonomic nervous system function in man. *European Journal of Clinical Pharmacology*, 38(1), 25-30. doi:[10.1007/BF00314798](https://doi.org/10.1007/BF00314798)

Reviews

1. **Ferrari, P.** (2018). Early kidney allograft loss: is there scope for improvement? *Transplant International*, 31(8), 864-866. doi:[10.1111/tri.13140](https://doi.org/10.1111/tri.13140)
2. Toews, M., Giancaspro, M., Richards, B., & **Ferrari, P.** (2017). Kidney paired donation and the "valuable consideration" problem: The experiences of Australia, Canada, and the United States. *Transplantation*, 101(9), 1996-2002. doi:[10.1097/TP.0000000000001778](https://doi.org/10.1097/TP.0000000000001778)
3. Ramanathan, G., Olynyk, J. K., & **Ferrari, P.** (2017). Diagnosing and preventing iron overload. *Hemodialysis International*, 21, S58-S67. doi:[10.1111/hdi.12555](https://doi.org/10.1111/hdi.12555)
4. **Ferrari, P.** (2016). Nurturing the benefits of pre-emptive kidney transplantation. *Nephrology Dialysis Transplantation*, 31(5), 681-682. doi:[10.1093/ndt/gfv383](https://doi.org/10.1093/ndt/gfv383)
5. **Ferrari, P.**, Weimar, W., Johnson, R. J., Lim, W. H., & Tinckam, K. J. (2015). Kidney paired donation: Principles, protocols and programs. *Nephrology Dialysis Transplantation*, 30(8), 1276-1285. doi:[10.1093/ndt/gfu309](https://doi.org/10.1093/ndt/gfu309)
6. Hadaya, K., Fehr, T., Risi, B., Ferrari-Lacraz, S., Villard, J., & **Ferrari, P.** (2015). Kidney paired donation a plea for a Swiss national programme. *Swiss Medical Weekly*, 145. doi:[10.4414/smw.2015.14083](https://doi.org/10.4414/smw.2015.14083)
7. Cantwell, L., Woodroffe, C., Holdsworth, R., & **Ferrari, P.** (2015). Four years of experience with the Australian kidney paired donation programme. *Nephrology*, 20(3), 124-131. doi:[10.1111/nep.12369](https://doi.org/10.1111/nep.12369)
8. Woodroffe, C., & **Ferrari, P.** (2013). The Australian paired kidney eXchange (AKX) program - The first three years. In *Transplant Nurses Journal* Vol. 22 (pp. 10-14).
9. **Ferrari, P.** (2013). Treating blood pressure to goal by overcoming therapeutic inertia and non-adherence. *Salud(i)Ciencia*, 19(8), 723-727.
10. Hart, J., Dyer, J. R., Clark, B. M., McLellan, D. G., Perera, S., & **Ferrari, P.** (2012). Travel-related disseminated *Penicillium marneffei* infection in a renal transplant patient. *Transplant Infectious Disease*, 14(4), 434-439. doi:[10.1111/j.1399-3062.2011.00700.x](https://doi.org/10.1111/j.1399-3062.2011.00700.x)
11. **Ferrari, P.** (2010). The role of 11 β -hydroxysteroid dehydrogenase type 2 in human hypertension. *Biochimica et Biophysica Acta - Molecular Basis of Disease*, 1802(12), 1178-1187. doi:[10.1016/j.bbadis.2009.10.017](https://doi.org/10.1016/j.bbadis.2009.10.017)
12. **Ferrari, P.**, & De Klerk, M. (2009). Paired kidney donations to expand the living donor pool. *Journal of Nephrology*, 22(6), 699-707.
13. **Ferrari, P.** (2009). Licorice: A sweet alternative to prevent hyperkalemia in dialysis patients. *Kidney International*, 76(8), 811-812. doi:[10.1038/ki.2009.282](https://doi.org/10.1038/ki.2009.282)
14. Woodroffe, C., & **Ferrari, P.** (2009). The western australian experience with a kidney paired donation programme. *Transplant Nurses Journal*, 18(2), 5-8.
15. **Ferrari, P.**, Woodroffe, C., & Christiansen, F. T. (2009). Paired kidney donations to expand the living donor pool: The Western Australian experience. *Medical Journal of Australia*, 190(12), 700-703.
16. **Ferrari, P.** (2007). The challenge of renal cystic disease and its association with hypertension, age and abnormal potassium handling. *Journal of Hypertension*, 25(7), 1347-1349. doi:[10.1097/HJH.0b013e32814db544](https://doi.org/10.1097/HJH.0b013e32814db544)

17. **Ferrari, P.** (2007). Prescribing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease. *Nephrology*, 12(1), 81-89. doi:[10.1111/j.1440-1797.2006.00749.x](https://doi.org/10.1111/j.1440-1797.2006.00749.x)
18. **Ferrari, P.**, & Bonny, O. (2004). Diagnosis and prevention of uric acid stones. *Therapeutische Umschau*, 61(9), 571-574. doi:[10.1024/0040-5930.61.9.571](https://doi.org/10.1024/0040-5930.61.9.571)
19. **Ferrari, P.** (2003). Best Practice and Research Clinical Endocrinology and Metabolism: Preface. *Best Practice and Research: Clinical Endocrinology and Metabolism*, 17(4). doi:[10.1016/j.beem.2003.09.002](https://doi.org/10.1016/j.beem.2003.09.002)
20. Bianchetti, M. G., Simonetti, G. D., & **Ferrari, P.** (2003). The distinction between Liddle syndrome and apparent mineralocorticoid excess. *Pediatr Nephrol*, 18(6), 607-608. doi:[10.1007/s00467-002-1049-1](https://doi.org/10.1007/s00467-002-1049-1)
21. **Ferrari, P.**, & Bonny, O. (2003). Treatment of hypertension in chronic kidney diseases. *Praxis*, 92(50), 2145-2152. doi:[10.1024//0369-8394.92.50.2145](https://doi.org/10.1024//0369-8394.92.50.2145)
22. **Ferrari, P.** (2003). Cortisol and the renal handling of electrolytes: Role in glucocorticoid-induced hypertension and bone disease. *Best Practice and Research: Clinical Endocrinology and Metabolism*, 17(4), 575-589. doi:[10.1016/S1521-690X\(03\)00053-8](https://doi.org/10.1016/S1521-690X(03)00053-8)
23. Schumacher, M., Van Vliet, B. N., & **Ferrari, P.** (2003). Kidney transplantation in rats: An appraisal of surgical techniques and outcome. *Microsurgery*, 23(4), 387-394. doi:[10.1002/micr.10139](https://doi.org/10.1002/micr.10139)
24. **Ferrari, P.**, & Bonny, O. (2003). *Forms of Mineralocorticoid Hypertension* (Vol. 66). doi:[10.1016/S0083-6729\(03\)01004-5](https://doi.org/10.1016/S0083-6729(03)01004-5)
25. **Ferrari, P.** (2002). Genetics of the mineralocorticoid system in primary hypertension. *Current Hypertension Reports*, 4(1), 18-24. doi:[10.1007/s11906-002-0048-8](https://doi.org/10.1007/s11906-002-0048-8)
26. **Ferrari, P.**, Bianchetti, M., & Frey, F. J. (2001). Juvenile hypertension, the role of genetically altered steroid metabolism. *Hormone Research*, 55(5), 213-223. doi:[10.1159/000049999](https://doi.org/10.1159/000049999)
27. **Ferrari, P.**, & Uehlinger, D. E. (2000). Which hypertensive patients requires diuretic treatment?. *Therapeutische Umschau*, 57(6), 380-385. doi:[10.1024/0040-5930.57.6.380](https://doi.org/10.1024/0040-5930.57.6.380)
28. **Ferrari, P.**, & Frey, F. J. (2000). Diuretics, mode of action in the kidney. *Therapeutische Umschau*, 57(6), 345-350. doi:[10.1024/0040-5930.57.6.345](https://doi.org/10.1024/0040-5930.57.6.345)
29. **Ferrari, P.**, & Krozowski, Z. (2000). Role of the 11 β -hydroxysteroid dehydrogenase type 2 in blood pressure regulation. *Kidney International*, 57(4), 1374-1381. doi:[10.1046/j.1523-1755.2000.00978.x](https://doi.org/10.1046/j.1523-1755.2000.00978.x)
30. **Ferrari, P.** (2000). How relevant is the trough-to-peak ratio? *Schweizerische Medizinische Wochenschrift*, 130(9), 329-335.
31. **Ferrari, P.** (1999). Molecular genetics of human hypertension. *Therapeutische Umschau*, 56(1), 5-11. doi:[10.1024/0040-5930.56.1.5](https://doi.org/10.1024/0040-5930.56.1.5)
32. **Ferrari, P.** (1999). Hypertension is a frequent illness. *Therapeutische Umschau*, 56(1), 3-4. [PMID 10067127](https://pubmed.ncbi.nlm.nih.gov/10067127/)
33. **Ferrari, P.** (1998). Pharmacogenomics: a new approach to individual therapy of hypertension? *Curr Opin Nephrol Hypertens*, 7(2), 217-222. [PMID 9529626](https://pubmed.ncbi.nlm.nih.gov/9529626/)

34. Bianchi, G., & **Ferrari, P.** (1995). A genetic approach to the pathogenesis of primary hypertension and to its treatment. In *Clinical and Experimental Pharmacology and Physiology* Vol. 22. [PMID 8846504](#)
35. **Ferrari, P.** (1993). Diabetes mellitus and kidney diseases. Microalbuminuria and antihypertensive therapy. In *Therapiewoche Schweiz* Vol. 9 (pp. 776-782).
36. Weidmann, P., & **Ferrari, P.** (1993). Hypertension, insulin, and alpha 1-blockade. *Journal of Clinical Pharmacology*, 33(9), 895-899.
37. **Ferrari, P.**, & Frey, F. J. (1993). Immunosuppressive therapy of glomerulonephritis - Controlled trials. *Therapeutische Umschau*, 50(2), 119-129.
38. Weidmann, P., De Courten, M., **Ferrari, P.**, & Böhlen, L. (1993). Serum lipoproteins during treatment with antihypertensive drugs. *Journal of Cardiovascular Pharmacology*, 22(12), S98-S105.
39. Weidmann, P., de Courten, M., & **Ferrari, P.** (1992). Effect of diuretics on the plasma lipid profile.. *Eur Heart J*, 13 Suppl G, 61-67. [PMID 1486908](#)
40. Weidmann, P., Boehlen, L. M., De Courten, M., & **Ferrari, P.** (1992). Antihypertensive therapy in diabetic patients. *Journal of Human Hypertension*, 6(SUPPL. 2). [PMID 1289510](#)
41. Weidmann, P., Allemann, Y., & **Ferrari, P.** (1992). Rational assessment procedure in hypertension. *Schweizerische Rundschau für Medizin Praxis*, 81(23), 756-766. [PMID 1604089](#)
42. Weidmann, P., & **Ferrari, P.** (1992). Antihypertensive treatment in the nineties. *Schweizerische Rundschau für Medizin/Praxis*, 81(7), 188-198. [PMID 1535954](#)
43. Weidmann, P., **Ferrari, P.**, Allemann, Y., Ferrier, C., & Shaw, S. G. (1991). Developing essential hypertension: A syndrome involving ANF deficiency? *Canadian Journal of Physiology and Pharmacology*, 69(10), 1582-1591. doi:[10.1139/y91-235](#)
44. **Ferrari, P.**, Rosman, J., & Weidmann, P. (1991). Antihypertensive agents, serum lipoproteins and glucose metabolism. *The American Journal of Cardiology*, 67(10). doi:[10.1016/0002-9149\(91\)90817-5](#)
45. Weidmann, P., & **Ferrari, P.** (1991). Central role of sodium in hypertension in diabetic subjects. *Diabetes Care*, 14(3), 220-232. doi:[10.2337/diacare.14.3.220](#)
46. **Ferrari, P.**, & Weidmann, P. (1990). Insulin, insulin sensitivity and hypertension. *Journal of Hypertension*, 8(6), 491-500. doi:[10.1097/00004872-199006000-00001](#)

Book chapters

1. **Ferrari, P.** (2012). The history of paired kidney donation in Australia. In: More Than a Footnote, The Story of Organ Transplantation in Australia and New Zealand. Eds: Brian D Tait, 95-108.
2. **Ferrari, P.**, Bianchetti MG. (2011). Diagnostic Investigations in Endocrine Disorders of Sodium Regulation. In: Diagnostics of Endocrine Function in Children and Adolescents Eds: Ranke MB, Mullis PE, Karger, Basel, Switzerland, 210-235.
3. **Ferrari, P.** (2008). Resistant hypertension. In: Clinical case studies. Eds: Harris D. BC Decker Inc, Sydney, Australia.
4. **Ferrari, P.**, Funder JW. (2007). 11 β -hydroxysteroid dehydrogenase. In: Sodium in Health and Disease. Eds: Burnier M. Marcel Dekker Inc, New York, USA, 157-174.
5. **Ferrari, P.**, Yeap BB. (2007). The hypertensive patient with laboratory findings: Role of cortisol. In: Advanced therapy in hypertension and vascular disease. Eds: Emile R. Mohler III, Raymond R. Townsend. BC Decker Inc Hamilton, Ontario, Canada, 339-346.
6. **Ferrari, P.** (2001). Nephrologie, Hypertonie. In: Notfall Vademecum SURF. Furger Ph (Ed.) Médecine & Hygiène, Genève, 32-42.
7. **Ferrari, P.** (2001). Néphrologie, Electrolytes. In: Guide Medical Therapeutique SURF. Furger Ph (Ed.) Médecine & Hygiène, Genève, 219-242.
8. Lukes A, **Ferrari, P.** (2000.) Neurovascular compression of the ventrolateral medulla in essential hypertension. In: Clinical cases in hypertension: specific treatment strategies. Sleight P, Mancia G, Messerli F, Opie L (Eds.) Excerpta Medica, Almere, Vol 2, 179-183.
9. **Ferrari, P.**, Gabutti L. (1998). Renal artery stenosis as a culprit. In: Clinical cases in hypertension: specific treatment strategies. Sleight P, Mancia G, Messerli F, Opie L (Eds.) Excerpta Medica, Almere, Vol 1, 109-119.
10. **Ferrari, P.**, Frey F. (1996). Autoimmunopathien der Nieren. In: Klinische Immunologie. Peter HH, Pichler WJ (Eds.) Urban & Schwarzenberg, München, pp. 556-571.
11. Weidmann P, **Ferrari, P.**, Shaw SG. (1992). Renin in diabetes mellitus. In: The Renin-Angiotensin System. Robertson JIS, Nicholls G (Eds.) Gower Medical Publishing, London, Vol 2, pp. 75.1-75.26.
12. Weidmann P, **Ferrari, P.**, Rosman JB, de Courten M. (1992). Current antihypertensive drugs and serum lipoproteins. In: Hypertension, Atherosclerosis and Lipids. Van Zwieten PA, Mancia G, Brodde OE (Eds.) Royal Society of Medicine Services Limited, London/New York, International Congress and Symposium Series Number 191, pp. 35-56.
13. Weidmann P, **Ferrari, P.**, Allemann Y, Shaw SG. (1991). Vaskuläre und metabolische Dysregulation bei Nachkommen essentiell hypertensiver Eltern. Proceedings of the 15. Nephrologisches Seminar, Heidelberg, pp. 1-9.
14. Weidmann P, **Ferrari, P.**, Allemann Y, Shaw SG. (1991). Developing essential hypertension: does it involve a syndrome of relative ANF-deficiency. In: Physiological and clinical aspects of atrial natriuretic factor. Adnot S, Cantin M, Charbier PE (Eds.) Flammarion, Paris, 171-193.
15. Weidmann P, **Ferrari, P.**, Allemann Y, Shaw SG. (1991). The role of sodium retention and atrial natriuretic factor in diabetes-associated as compared with essential hypertension. In: Diabetes. Rifkin H, Colwell JA, Taylor SI (Eds.) Elsevier Science Publisher, New York, pp. 292-298.

16. **Ferrari, P.**, Weidmann P. Insulinsensitivität: Pathophysiologische und therapeutische Bedeutung bei Hypertonie. (1990). Proceedings of the 14. Nephrologisches Seminar, Heidelberg, pp. 34-44.
17. Weidmann P, Trost BN, **Ferrari, P.** (1989). Treatment of the hypertensive diabetic: focus on calcium channel blockade. In: How should elderly hypertensive patient be treated? Zanchetti A and Omae T (Eds.) Springer, Heidelberg, pp. 85-99.

Case reports

1. Viecelli, A., Jamboti, J., Waring, A., Banham, N., & **Ferrari, P.** (2014). Acute kidney injury due to decompression illness. *Clinical Kidney Journal*, 7(4), 380-382. doi:[10.1093/ckj/sfu048](https://doi.org/10.1093/ckj/sfu048)
2. Agarwal, A., **Ferrari, P.**, Macmillan, J., & Singer, R. (2007). Venlafaxine to treat severe hypotension. *Nephrology*, 12(6), 622. doi:[10.1111/j.1440-1797.2007.00853.x](https://doi.org/10.1111/j.1440-1797.2007.00853.x)
3. Yeap, B. B., Platell, C. F., & **Ferrari, P.** (2005). Apparent Addison's Disease Following Ileostomy. *Nephrology*, 10(5), 537-538. doi:[10.1111/j.1440-1797.2005.00492.x](https://doi.org/10.1111/j.1440-1797.2005.00492.x)
4. Fuster, D., Frey, F. J., & **Ferrari, P.** (2000). Life-threatening hyperkalemia as a consequence of the new treatment strategies of congestive heart failure. *Praxis*, 89(49), 2073-2076. [PMID 11190849](https://pubmed.ncbi.nlm.nih.gov/11190849/)
5. Frey, F. J., & **Ferrari, P.** (2000). Pastis and hypertension-What is the molecular basis?. *Nephrology Dialysis Transplantation*, 15(10), 1512-1514. doi:[10.1093/ndt/15.10.1512](https://doi.org/10.1093/ndt/15.10.1512)
6. Zenhäusern, R., Tobler, A., Leoncini, L., Hess, O. M., & **Ferrari, P.** (2000). Fatal cardiac arrhythmia after infusion of dimethyl sulfoxide-cryopreserved hematopoietic stem cells in a patient with severe primary cardiac amyloidosis and end-stage renal failure. *Ann Hematol*, 79(9), 523-526. Retrieved from [PMID 11043425](https://pubmed.ncbi.nlm.nih.gov/11043425/)
7. Nohl, F., & **Ferrari, P.** (1998). Drug-induced gingival hyperplasia. *Therapeutische Umschau*, 55(9), 573-575. <https://www.ncbi.nlm.nih.gov/pubmed/9789475> . [PMID 9535997](https://pubmed.ncbi.nlm.nih.gov/9535997/)
8. **Ferrari, P.**, & Weidmann, P. (1990). Insulin sensitivity in humans: Alterations during drug administration and in essential hypertension. *Mineral and Electrolyte Metabolism*, 16(1), 16-24. [PMID 2182992](https://pubmed.ncbi.nlm.nih.gov/2182992/)
9. Rosman, J., Weidmann, P., & **Ferrari, P.** (1990). Antihypertensive drugs and serum lipoproteins. In *Journal of Drug Development, Supplement Vol. 3* (pp. 129-139).
10. **Ferrari, P.**, & Weidmann, P. (1989). Lipoproteins during antihypertensive therapy. Study supported by the Swiss National Science Foundation. *South African Medical Journal, Suppl*, 13-17.

Letters

1. **Ferrari, P.** (2013). Letter to the Editor. Facilitators to national kidney paired donation program. *Transplant International*, 26(5). doi:[10.1111/tri.12077](https://doi.org/10.1111/tri.12077)
2. Makrounas-Kirchmann, K., Glover-Koudounas, S., & **Ferrari, P.** (2010). Letter to the Editor. *Clinical Therapeutics*, 32(2), 397. doi:[10.1016/S0149-2918\(10\)00069-X](https://doi.org/10.1016/S0149-2918(10)00069-X)
3. Sealey, J. E., Blumenfeld, J., Laragh, J. M., & **Ferrari, P.** (2005). Prorenin cryoactivation as a possible cause of normal renin levels in patients with primary aldosteronism (multiple letters). *Journal of Hypertension*, 23(2), 459-460. doi:[10.1097/00004872-200502000-00030](https://doi.org/10.1097/00004872-200502000-00030)
4. Kancha, K., Lee, J., Ahmed, Z., Kashyap, A. S., Anand, K. P., Kashyap, S., . . . Bartorelli, A. L. (2004). Hemofiltration and the Prevention of Radiocontrast-Agent-Induced Nephropathy [1] (multiple letters). *New England Journal of Medicine*, 350(8), 836-838. doi:[10.1056/NEJM200402193500816](https://doi.org/10.1056/NEJM200402193500816)
5. **Ferrari, P.**, & Vogt, B. (2004). Letter to the Editor. Hemofiltration and the prevention of radiocontrast-agent-induced nephropathy. *The New England journal of medicine*, 350(8). doi:[10.1056/NEJM200402193500816](https://doi.org/10.1056/NEJM200402193500816)
6. Bianchetti, M. G., Simonetti, G. D., **Ferrari, P.**, & Assadi, F. K. (2003). The distinction between Liddle syndrome and apparent mineralocorticoid excess (multiple letters) [1]. *Pediatric Nephrology*, 18(6), 607-609.
7. **Ferrari, P.** (2002). Endothelin 1 type a receptor antagonism prevents vascular dysfunction and hypertension induced by 11beta-hydroxysteroid dehydrogenase inhibition: role of nitric oxide. *Circulation*, 105(17).
8. **Ferrari, P.** (2000). In Vivo Measurements of Renal 11 β -Hydroxysteroid Dehydrogenase Type 2 Activity. *Journal of Clinical Endocrinology and Metabolism*, 85(12), 4922-4923. doi:[10.1210/jcem.85.12.7076-4](https://doi.org/10.1210/jcem.85.12.7076-4)
9. Quinkler, M., Oelkers, W., Diederich, S., & **Ferrari, P.** (2000). In vivo measurement of renal 11 β -hydroxysteroid dehydrogenase type 2 activity [2] (multiple letters). *Journal of Clinical Endocrinology and Metabolism*, 85(12), 4921-4923. doi:[10.1210/jc.85.12.4921](https://doi.org/10.1210/jc.85.12.4921)
10. Gabutti, L., & **Ferrari, P.** (1999). Arterial hypertension and rapidly progressive renal failure. *Therapeutische Umschau*, 56(1), 55-60. doi:[10.1024/0040-5930.56.1.55](https://doi.org/10.1024/0040-5930.56.1.55)
11. **Ferrari, P.**, Graves, S. W., Hollenberg, N. K., Tao, Q. F., & Price, D. A. (1997). Sodium pump isoform specificity for digitalis-like factor [2] (multiple letters). *Hypertension*, 30(5), 1296-1297.
12. **Ferrari, P.**, & Trost, B. N. (1990). A case from practice (169). Liquorice-induced pseudohyperaldosteronism in a previously alcoholic woman caused by the drinking of an alcohol-free Pastis substitute beverage. *Schweizerische Rundschau fur Medizin Praxis*, 79(12), 377-378.
13. Rosman, J. B., **Ferrari, P.**, & Donker, A. J. M. (1990). Protein restriction and the progression of renal insufficiency (II). *New England Journal of Medicine*, 322(22), 1609-1611. doi:[10.1056/NEJM199005313222216](https://doi.org/10.1056/NEJM199005313222216).